Synchron has been innovating the neurotechnology industry since 2012, developing minimally-invasive solutions to address the limitations of the human body, particularly avoiding the need for open brain surgery.

Thomas Oxley

Nicholas Opie

Synchron

Synchron is a leading implantable brain computer interface company. The stentrode is the first commercial implantable brain computer interface to receive an FDA IDE for in human clinical trials.

Forepont Capital Partners

General Advance

re.Mind Capital

Shanda Group

Khosla Ventures

METIS innovative

Subversive Capital

University of Melbourne

Arani Bose

Thomas Reardon

Bezos Expeditions

Greenoaks

Alumni Ventures

Reliance Industries

Moore Strategic Ventures

We’re excited to announce completion of patient enrollment in our US-based COMMAND trial, which enrolled a total of six patients and is being conducted under the first investigational device exemption (IDE) awarded by the FDA to a company assessing a permanently implanted BCI. 🧠🧠🧠

The early feasibility study assesses safety while evaluating quantified efficacy measures of the Synchron Switch™ motor #neuroprosthesis in patients with severe paralysis.

Thank you to our clinical sites: Mount Sinai Health System in New York City, University at Buffalo Neurosurgery and UPMC, in collaboration with Carnegie Mellon University College of Engineering. The study is being conducted with support from the NIH BRAIN Initiative.

“We would like to thank everyone who partnered with us to complete this important clinical trial enrollment milestone, especially patients and caregivers as well as the physicians and research staff at our clinical sites in the United States,” said Thomas Oxley, MD, PhD, CEO & Founder, Synchron. “We look forward to announcing the results from our COMMAND study and will continue to advance development of Synchron Switch towards a pivotal clinical trial in the US.”

Read the full release:
👇👇👇

https://lnkd.in/eRitdTUK #BCI #braincomputerinterface #clinicaltrials

We are pleased to hear that Professor Nicholas Opie, a University of Melbourne professor and the founding director of brain interface platform  Synchron, has been awarded the Paul Shetler Disruptor of the Year Award at the InnovationAus 2023 Awards for Excellence for his pioneering work in neural interfaces.

Professor Nicholas Opie also recently delivered the 2023 Melbourne Connect Oration, where he shared firsthand the incredible journey of how the concept of the Stentrode was translated into clinical trials and its immense potential to change lives.

Learn more: https://lnkd.in/ghyiJQTU

#melbconnect  InnovationAus.com

Thank you to everyone who stopped by our booth at #ACRM2023! We enjoyed participating in insightful discussions and seeing the wonderful presentations on rehabilitation research and medicine.

A special thank you to all who attended our CEO, Thomas Oxley's session with Dr. David Putrino and Dr. Raul Nogueira on "Brain Computer Interfaces Restoring Autonomy to People with Severe Paralysis." We would also like to extend our appreciation to Field Clinical Engineer, Maria Nardozzi, for representing Synchron during the didactic lecture on “Advanced Technologies for Neurorehabilitation: Brain-Based Applications,” and the valuable contributions from Nick Singer! 🧠 
 
We look forward to continuing the conversation and seeing everyone next year! 
 
#Synchron #ACRM #RehabConference #BCI #BCITechnology #BrainComputerInterface #Rehabilitation #RehabilitationResearch #RehabMedicine #PMandR #MedEd #CognitiveRehabilitation #CognitiveCare #ClinicalPractice #NeurologicalDiseases #Neurology #Neuroplasticity #NeuroRehabilitation #MedTech ACRM | American Congress of Rehabilitation Medicine

Join us today, November 1st, at 2:15 PM ET as our CEO, Thomas Oxley, presents the latest advancements in brain-computer interface (BCI) technology at #ACRM2023. He will discuss their transformative impact on individuals with severe paralysis, along with Dr. David Putrino from Icahn School of Medicine at Mount Sinai and Dr. Raul Nogueira from the University of Pittsburgh School of Medicine. They cover the following learning objectives:  
 
🧠 Describe the current state of the art for brain computer interfaces (BCI) for enabling individuals with paralysis to operate an external device. 
🧠 Define current safety and efficacy challenges in the field of BCI. 
🧠 Describe how future improvements in BCI may enable individuals with paralysis to gain improved independence and quality of life. 
 
If you are attending the conference, this session is one not to miss, and be sure to visit Booth 811C to meet the Synchron team! 
 
👉 For more details, visit ACRM2023.eventscribe.net. 
 
#Synchron #ACRM #RehabConference #BCI #BCITechnology #BrainComputerInterface #Rehabilitation #RehabilitationResearch #RehabMedicine #PMandR #MedEd #CognitiveRehabilitation #CognitiveCare #ClinicalPractice #NeurologicalDiseases #Neurology #Neuroplasticity #NeuroRehabilitation #MedTech ACRM | American Congress of Rehabilitation Medicine

We are in #Atlanta for the #ACRM2023 100th Annual Conference! Synchron is exhibiting, and we look forward to connecting with industry and thought leaders across the rehabilitation research and medicine space. 
  
📆 Tomorrow, November 1st, at 2:15 PM ET, our CEO, Thomas Oxley, will be presenting alongside Dr. David Putrino, Director of Rehabilitation Innovation at Icahn School of Medicine at Mount Sinai, and Dr. Raul Nogueira, Endowed Professor of Neurology and Neurosurgery at the University of Pittsburgh School of Medicine. They will engage in an important conversation on "Brain Computer Interfaces Restoring Autonomy to People with Severe Paralysis.” Don't forget to mark your calendars!  
   
👉 Check out the full agenda and join us here: ACRM.org/register  
   
If you are attending the event and have an interest in exploring the future of #BCI-based treatment, we also encourage you to meet Maria Nardozzi and Nick Singer of Synchron at Booth 811C. 
 
#Synchron #ACRM #RehabConference #BCITechnology #BrainComputerInterface #Rehabilitation #RehabilitationResearch #RehabMedicine #PMandR #MedEd #CognitiveRehabilitation #CognitiveCare #ClinicalPractice #NeurologicalDiseases #Neurology #Neuroplasticity #NeuroRehabilitation #MedTech ACRM | American Congress of Rehabilitation Medicine

Join the Synchron Team! We're #hiring a Senior Clinical Scientist with extensive clinical research experience and an excellent understanding of brain-computer interfaces (#BCI). Be a part of our mission to develop a first-in-class commercial BCI, helping over 100 million people worldwide with severe motor impairment regain connection to the world.  
 
Learn more and apply now: bit.ly/3Sjk4iP  
 
🧠 Explore more career opportunities: Synchron.com/Careers   
 
Brooklyn preferred; however, remote US-based will be considered.

#Synchron #SynchronNY #BrainComputerInterface #Neuroscience #Neurology #ClinicalScience #BCIResearch #Healthcare #HealthTech #Medtech #Neurotech #Innovation #MedicalDevice #ClinicalTrials #STEMCareers #NYCJobs #Brooklyn #UnlockingNaturalHighways

It was great to come together with our Chief Medical Officer, Dr. J Mocco of Mount Sinai Health System, and a distinguished group of experts, including Dr. Shahram Majidi of Mount Sinai Health System, Dr. Raul Nogueira of UPMC, Dr. Elad Levy, Dr. Nandor Pinter, MD, & Dr. Kenneth Snyder of University at Buffalo Neurosurgery (UBNS), Dr. Jens Fiehler of Universitätsklinikum Hamburg Eppendorf, and Dr. Rahul Sharma of Stanford University School of Medicine, to discuss next steps following successful enrollment for our COMMAND trial. Synchron secured the industry's first FDA-approved clinical trial for a permanently implanted brain-computer interface (BCI) in the United States. 

This milestone represents a significant advancement in minimally-invasive BCI technology. Our collective efforts aim to empower individuals with motor impairment by enabling them to control digital devices. This transformative technology holds the promise of positively impacting both users as well as their caregivers and families. 
 
We look forward to advancing a scalable BCI solution and sharing further updates as we progress!  
 
🧠 Learn more about our innovative technology at Synchron.com/Technology.  
 
#Synchron #SynchronNY #COMMANDTrial #SynchronSwitch #Stentrode #ClinicalTrials #BCI #BrainComputerInterface #BCIAdvancements #MedicalDevice #Medtech #Neurology #Neuroscience #Neurotech #UnlockingNaturalHighways

Our Chief Commercial Officer Kurt Haggstrom spoke at DeviceTalks West about the history of #BCI, where the technology is today, and where it’s heading. 

Great to see everyone from the #medtech #medicaldevice community and looking forward to seeing you all at the next event!

Sharing the article from Medical Design & Outsourcing: 

https://lnkd.in/eTjb9HAi

Thanks MassDevice Tom Salemi and team for inviting our Chief Commercial Officer Kurt Haggstrom to present on our #BCI journey at Synchron. 

Great crowd and great questions today! 🙏🙏

#braincomputerinterface #neuroprosthesis

Thanks Jim Hammerand, managing editor at Medical Design & Outsourcing for speaking with our CEO Thomas Oxley and dispelling some myths about #BCIs. 

The biggest BCI misconception is that a BCI to treat paralysis must restore the movement of a patient’s arm or leg, Oxley said. That might be the case one day, but for now Synchron is focused on a simpler task.

“What we’re focused on is building a control language that can lead to control of a range of things, which may include an arm or a leg or exoskeleton or prosthesis, but actually, in the first instance, is controlling smart devices — iPhones,” he said. 📱📱📱

Read the full article: 

https://lnkd.in/esj6gWAt

Metric
Company Name	Synchron
Symbol
MSH ID	COM:SYNCHRON
Market	PRIVATE
Sector	Healthcare
Industry	Neurotechnology
Country	US
Stage	Series C
Employee Count	133
Website	synchron.com
LinkedIn	synchron-inc.
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	9.38K
Web Traffic Growth	0.04
Valuation
Raised Capital	75M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:SYNCHRON

Synchron

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue